Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Recursion Pharmaceuticals (RXRX) has shown volatility recently, with a 3.13% decline on July 8, 2026, amidst broader market movements. The company is preparing for an earnings report, expected to show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results